

Our Position Regarding the Matter Disclosed by Takara Bio Inc.

Today, Takara Bio Inc. (hereinafter “Takara Bio”), with which we have entered into a business alliance, announced the implementation of structural reforms to its business (hereinafter, the “Matter”).

With respect to our pipeline NIB103, we and Takara Bio have entered into a business alliance agreement concerning the joint development and commercialization of NIB103 (hereinafter, the “Agreement”), under which Takara Bio is responsible for manufacturing-related operations.

At this time, pursuant to the Agreement, we do not anticipate that the Matter will have an immediate material impact on the development plan for NIB103, while we will continue to confirm the implications of the Matter.

Should any matter requiring disclosure arise in the future, we will promptly make an announcement.

Contact for inquiries or additional information
2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan
Noile-Immune Biotech Inc.
pr@noile-immune.com